Consumers Are Replacing Pharmaceuticals With Medical Marijuana

The Fresh Toast

Consumers Are Replacing Pharmaceuticals With Medical Marijuana In recent years, certain states that have medical and/or recreational cannabis programs in place have experienced decreases in the number of opioid overdoses. The post Consumers Are Replacing Pharmaceuticals With Medical Marijuana appeared first on The Fresh Toast. Cannabis Medical Marijuana News opioids pharmaceuticals

BBC Report: EU Approves , “Epidyolex” GW Pharmaceuticals

Cannabis Law Report

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. The medication, developed by GW Pharmaceuticals, will be used in combination with another epilepsy medication called clobazam. It is important that the pharmaceutical industry continues to work with the medical advisory body to ensure that drugs are cost effective and that its long-term effects are clear.” About GW Pharmaceuticals plc and Greenwich Biosciences, Inc.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

GW Pharmaceuticals loses $8 million over last quarter

Cannabis Law Report

GW Pharmaceuticals lost $8 million in its latest quarter – an improvement over the previous three-month period – but the United Kingdom-based medical cannabinoid company … Read More. Breaking News

Canada: Mydecine signs agreement with Applied Pharmaceutical Innovation (API) at the University of Alberta’s Faculty of Pharmacy and Pharmaceutical Sciences

Cannabis Law Report

The mycology-focused company has signed an agreement with Applied Pharmaceutical Innovation (API), … Read More. Mydecine ( MYCO.CN ) ( NLBIF ) is quickly upping its fungi authority. Psy Business & Law News Partnered With CFN

Europe Cannabis and Pain Management Devices on Cancer Pain Market – Major Technology Giants in Buzz Again | Cannabis Players:, GW Pharmaceuticals, UNIMED PHARMACEUTICALS, Valeant Pharmaceuticals, Insys Therapeutics

Cannabis Law Report

Europe Cannabis and Pain Management Devices on Cancer Pain market by key players: Cannabis Players: GW Pharmaceuticals. UNIMED PHARMACEUTICALS. Valeant Pharmaceuticals. Some of the players covered in the study are Cannabis Players:, GW Pharmaceuticals, UNIMED PHARMACEUTICALS, Valeant Pharmaceuticals, Insys Therapeutics, Axim Biotechnologies, Medical Marijuana, Zynerba, Pain Management Device Players:, Boston Scientific Crop.,

Aurora Cannabis and CTT Pharmaceutical Launch Sublingual Cannabis Wafers

Cannabis Life Network

8, 2019 /CNW/ – Aurora Cannabis Inc. (“Aurora”) (NYSE | TSX: ACB), the Canadian company defining the future of cannabis worldwide, and CTT Pharmaceutical Holdings, Inc., (“CTT”) (OTC | CTTH) announced […]. The post Aurora Cannabis and CTT Pharmaceutical Launch Sublingual Cannabis Wafers appeared first on Cannabis News | Lifestyle Tips | Expert Opinions | Stocks.

New data shows Cannabis replacing Alcohol and Pharmaceuticals in the U.S.

Leaf Science

study shows that more and more people are giving up alcohol and pharmaceuticals in favour of cannabis use. are moving away from alcohol and pharmaceuticals in favour of cannabis use. Taking cannabis user archetypes beyond the traditional medical/recreational binary, the study developed nine distinct cannabis consumer profiles and looked at their use of alcohol, pharmaceuticals and cannabis to gain greater insight into the full spectrum of consumer values, lifestyles and behaviours.

Benchmark Signs A Strategic Cooperation With China-Based Zejiang Yatai Pharmaceutical

Canna Newswire

To create, develop and market a variety of high content cannabinoid based pharmaceuticals, natural health products and cosmetics for international markets. CSE: BBT ) ( FSE: BBW ) ( OTC: BHHKF ) (“Benchmark” or the “Company”) a federally-licensed producer and distributor of medical-grade cannabis, is pleased to announce that it has signed a non-binding letter of intent of strategic cooperation with China-based Zhejiang Yatai Pharmaceutical Co.,

EU Licensed European Pharmaceutical Company, Freia Farmaceutici Srl

Cannabis Law Report

TSXV: LG and OTC-QB: LGGCF) (“ LGC ”) is pleased to announce that it has paid the 2 nd Tranche, as contractually agreed, in acquiring an equity interest in the Italian pharmaceutical company, Freia Farmaceutici Srl (“Freia”). It should be noted that Freia’s products are currently authorized under the framework of pharmaceutical law and not subject to the evolving, provisional regulation of cannabis. This EU pharmaceutical entity is an optimal addition to LGC.

InMed Pharmaceuticals Announces Completed Enrollment in Phase 1 Clinical Trial of INM-755 CBN Cream in Healthy Subjects

Puff Puff Post

SOURCE InMed Pharmaceuticals Inc. VANCOUVER, March 10, 2020 /CNW/ – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today reported completed enrollment in its first Phase 1 clinical trial with INM-755 in healthy subjects (Study 755-101-HV).

Benchmark Signs Definitive Investment Cooperation Agreement with China-Based Zhejiang Yatai Pharmaceutical

Canna Newswire

CSE: BBT ) ( FSE: BBW ) ( OTC: BHHKF ) (“Benchmark”, “BBT” or the “Company”) a federally-licensed producer and distributor of medical-grade cannabis, is pleased to report that it has signed a definitive agreement with China-based Zhejiang Yatai Pharmaceutical Co., “Zhejiang Yatai is a Top 500 Chinese corporation and is a leader and an innovator in the pharmaceutical industry. About Zhejiang Yatai Pharmaceutical Co.,

Breaking the stigma: Psychedelic Drugs

Cannabis Life Network

There are a lot of negative stigma surrounding psychedelic drugs. A large portion of the population and the government condemn these substances to be dangerous, addictive, and illegal. Although, that may be true when it comes to opiates or stimulants (such as heroin or cocaine).

Report: “Key pharmacological differences between side effects of refined, pharmaceutical CBD formulations and whole plant extracts:”

Cannabis Law Report

This differs sharply from the conventional course of cannabis medicine, which is to use whole, clean plant extracts to treat epilepsy and to gradually discontinue use of conventional pharmaceuticals. Another example of cannabinoid mono therapy is the THC pharmaceutical Marinol. on the new pharmaceutical, and that the vast majority of these side effects are not from any extract of Cannabis, including CBD. Why would a pharmaceutical company do this?

International Cannabis to Supply New Zealand’s NUBU Pharmaceuticals With Portfolio of Full-Spectrum Pharmaceutical THC/CBD Products

Cannabis Law Report

FWB: 8K51)(OTC: WLDCF) (the “Company” or “ ICC ” or “ International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). Founded in 2017, NUBU Pharmaceuticals is widely considered a first mover within New Zealand’s high-value medical cannabis industry. ICC International Cannabis Corp. CSE: WRLD.U)(FWB:

International Cannabis to Supply New Zealand’s NUBU Pharmaceuticals With Portfolio of Full-Spectrum Pharmaceutical THC/CBD Products

Cannabis Law Report

FWB: 8K51)(OTC: WLDCF) (the “Company” or “ ICC ” or “ International Cannabis”) is pleased to announce that the Company has entered into an exclusive supply and commercial rights agreement (the “Agreement”) with licensed New Zealand medical cannabis company, NUBU Pharmaceuticals (“NUBU”). Founded in 2017, NUBU Pharmaceuticals is widely considered a first mover within New Zealand’s high-value medical cannabis industry.

Cannabis Wire Investigates Lobbying Power Of “Greenwich Biosciences” The US Arm of GW Pharmaceuticals

Cannabis Law Report

The US subsidiary of GW Pharmaceuticals, behind the only FDA-approved cannabis extract-based medicine, is lobbying in all 50 states. Greenwich Biosciences , the United States subsidiary of the British GW Pharmaceuticals , registered to lobby in every single state in the country—including ones where all forms of cannabis are prohibited—over the last three years. The Incredibly Large Lobbying Footprint of Greenwich Biosciences.

Teva Pharmaceuticals has signed a deal with medical cannabis company Canndoc

Cannabis Law Report

According to information procured exclusively ahead of a formal announcement Friday, a subsidiary of NYSE-traded giant Teva Pharmaceuticals has signed a deal with medical cannabis company Canndoc to distribute its GMP products to pharma customers, including hospitals, health maintenance organizations (HMOs) and all pharmacies in Israel. Forbes report.

GW Pharmaceuticals announces that EPIDYOLEX® (cannabidiol) has been reclassified by the UK Home Office as a Schedule 5 drug

Cannabis Law Report

Here’s their press release: … Read More. Mark Taylor UK / EU Cannabis Compliance Blog

DEA loosens rules on prescription CBD drug Epidiolex

Leafly

Health Politics cannabidiol cbd Epidiolex GW Pharma GW PharmaceuticalsPrescription CBD tincture Epidiolex is coming to more patients. Cost: $32,500 per year. The post DEA loosens rules on prescription CBD drug Epidiolex appeared first on Leafly.

DEA 86

Canadian Company Signs “Definitive Agreement” With China-based Zhejiang Yatai Pharmaceutical Co., Ltd

Cannabis Law Report

CSE: BBT) (FSE: BBW) (OTC Pink: BHHKF) (“Benchmark”, “BBT” or the “Company”) a federally-licensed producer and distributor of medical-grade cannabis, is pleased to report that it has signed a definitive agreement with China-based Zhejiang Yatai Pharmaceutical Co., “Zhejiang Yatai is a Top 500 Chinese corporation and is a leader and an innovator in the pharmaceutical industry. Here’s the press release.

Press Release: Cabot Wealth Management Upped Gw Pharmaceuticals Plc (GWPH) Stake by $914,524; Share Price Declined; Unitedhealth Group (UNH) Holder New England Investment & Retirement Group Has Raised Stake

Cannabis Law Report

Cabot Wealth Management Inc increased its stake in Gw Pharmaceuticals Plc (GWPH) by 34.2% The institutional investor held 20,865 shares of the major pharmaceuticals company at the end of 2019Q2, valued at $3.60M, up from 15,548 at the end of the previous reported quarter. Cabot Wealth Management Inc who had been investing in Gw Pharmaceuticals Plc for a number of months, seems to be bullish on the $4.15B market cap company.

UK Opinion Piece: The Pharmaceutical Journal – The bar must not be lowered for medical cannabis

Cannabis Law Report

There have been calls to loosen regulations around medical cannabis to increase access for those who need it, but the government must resist and view cannabis with the same scrutiny as any other new medicine. Read all at ( paywall) [link]. Medical Cannabis News

Schultze Special Purpose Acquisition Corp. Announces Non-Binding Letter of Intent for a Business Combination with Clever Leaves, a Leading Pharmaceutical-Grade Multi-National Cannabis Operator

Cannabis Law Report

-With More than 1.9 Million Square Feet of Greenhouses, Clever Leaves is One of the Largest Cannabis Cultivation and Extraction Companies in the World- CORRECTION…by … Read More. Press Release US

Special Report: Pharmaceutical Marijuana Jamaica – Jamaica News Network interviewing MMJ Jamaica’s CEO on the company’s plans for marijuana cultivation and drug development

Cannabis Law Report

ST PETERSBURG, FL and KINGSTON, JAMAICA / ACCESSWIRE / May 10, 2020 / Duane Boise CEO of MMJ’s International’s Holding shares success for shipping natural … Read More. Press Release US

Portugal: KANNABEIRA® is a project and a registered trademark under the company Green Donation, Ltd. for the production R&D of pharmaceutical grade standardised cannabis.

Cannabis Law Report

for the production R&D of pharmaceutical grade standardised cannabis. Here the company shares their evolution with Health Europa, exploring the production of pharmaceutical grade standardised cannabis. KANNABEIRA® is a project and a registered trademark under the company Green Donation, Ltd. KANNABEIRA and standardised cannabis.

Thailand: Press Release Thailand Govt Pharma Organization “Pharmaceutical Organization, Department of Medical Cooperation, Research on Medical Marijuana Extracts For cancer patients with neurodegenerative epilepsy And nervous pain”

Cannabis Law Report

Press Release: Thailand Government Pharmaceutical Organization. The Pharmaceutical Organization, Department of Medical Affairs, signed a joint research on standard quality medical marijuana extracts for patients with chemo-allergic cancer, epilepsy, muscle contraction in patients with deteriorating nerve sheaths. Dr. Sophon Mektana, Advisor to the Minister of Public Health And the Chairman of the Pharmaceutical Organization Committee.

Australia’s MGC Pharmaceuticals finally gets cannabis cultivation research licence from the Australian Office of Drug Control.

Cannabis Law Report

Here’s the press release. The research will focus on the optimisation of breeding and cultivating processes and the extraction of material to assess their efficacy of medical cannabis on prostate, melanoma and other cancer cells. All intellectual property from the trials will be owned by MGC, which is funding the research.

The Truth About CBD

Nature's Way Medicine

Alternative Medicine cannabis education industry Logical Fallacies medical marijuana medicine News Pharmaceuticals Science-Based Medicine Skepticism about cbd dr. roman fake placebo skeptic skeptical skepticism thc truthIt's not easy gathering my wits and going public about this. I'm saying this and sticking my neck out as one individual opposing a multi-million(billion?) dollar industry.¹. The post The Truth About CBD appeared first on Nature's Way Medicine ®.

CBD 67

CBD Oil’s Wide Availablity Challenges Medical Research

Puff Puff Post

As farmers widely grow hemp for a variety of purposes, the pharmaceutical industry is not able to control the supply of CBD oil. The Department of Defense the provided grant making this study possible, in collaboration with GW Pharmaceuticals.

Opioids and Medical Cannabis: An Update on the Latest Information

Medical Marijuana 411

Cannabis Science Decriminalization Legalization Medical Marijuana 411 Politics Prohibition Addiction Opioids PharmaceuticalAmerica is in the throes of a major crisis. Opioid addiction has taken over many parts of the country and is taking a number of lives daily. The opioid crisis is at its breaking point right now. More people are spending time in hospitals or losing their lives to opioid overdose than ever before. According to the National Institute on Read Article.

Innovative Treatment for Seizures Released by Nature’s Grace and Wellness & JC Pharma Inc

Canna Newswire

MEDICAL CANNABIS PHARMACEUTICALSTwo Health and Wellness Powerhouses Collaborate to Help Those Suffering from Seizures Through an Innovative and Fast-Acting Intranasal Spray Solution. CHICAGO – July 11, 2019 / Canna Newswire / – Nature’s Grace and Wellness & JC Pharma, Inc. have reached a much- anticipated agreement that will make a groundbreaking, new seizure treatment available to the public.

Dr. Sanjay Gupta: Researchers Are Focused On Treating Autism With Marijuana

The Fresh Toast

Cannabis Featured Medical Marijuana News autism CBD oil Epilepsy GW Pharmaceuticals Sanjay GuptaLeading marijuana researchers now believe a cannabis compound could treat autism symptoms. Continue reading Dr. Sanjay Gupta: Researchers Are Focused On Treating Autism With Marijuana at The Fresh Toast.

Portugal Shoots Down Recreational Proposals As Medicinal Weed Goes Live

Cannabis Law Report

Medicinal cannabis was legalised in portugal in June 2018 by Parliament, however only one cannabis-based medication is legal in Portugal; Sativex, produced by British firm GW Pharmaceuticals. Featured Mark Taylor UK / EU Cannabis Compliance Blog aurora cannabis Aurora Portugal European Paraliament GW pharmaceuticals PLMJ portugal Portuguese Health Ministry sativexIf you wish to re-publish this story please do so with following accreditation. AUTHOR: Mark Taylor.

The Epidiolex Effect: Will Other CBD Drugs Receive FDA and DEA Approval?

Freedom Leaf

On September 28, the DEA designated Epidiolex —a plant-based CBD pharmaceutical manufactured by the UK-based GW Pharmaceuticals—a Schedule V drug in the government’s list of controlled substances. While GW Pharmaceuticals’ Epidiolex has received a Schedule V designation from the DEA, all other CBD formulations remain in Schedule I. . Sales of the pharmaceutical CBD product Epidiolex are expected to comprise less than a third of that projected total.

DEA 47

CBD to the Rescue

Project CBD

Life-threatening side effects from pharmaceuticals led one man to try cannabis. In this testimonial, he shares how cannabis helped him overcome refractory lockjaw and severe nerve pain

The Evolving Regulatory Status of Cannabidiol

Project CBD

Food and Drug Administration ( FDA ) announced its first-ever approval of a marijuana-derived pharmaceutical drug On June 25, 2018, the U.S.

Synthetic CBD and Solvents in Epidiolex?

Cannabis Life Network

GW Pharmaceuticals has been creating unusual blends of clinical cannabis for over two decades. Blog Featured Health Marijuana News Science Technology abnormal cbd CBD Epidiolex ethanol gpr GW Pharmaceuticals synthetic cbdEpidiolex is an abnormal, proprietary cannabidiol tincture that was developed for epilepsy. This clinical concoction has been under some well-deserved criticism for several reasons, such as a liver damage warning.